Simplified Triple Delivery

CONTACT GSK 1-XXX-XXX-XXXX

Simplify delivery of triple therapy

TRELEGY offers once-daily triple therapy for patients with COPD

Swipe right and scroll to see the whole table below.

ICS (FF) helps decrease inflammation in the lungs. The precise mechanism through which FF affects COPD symptoms is not known. LABA (VI) stimulates beta2-receptors in the airway smooth muscle, leading to bronchodilation. LAMA (UMEC) inhibits M3 receptors in the airways to relax smooth muscle tone, leading to bronchodilation.
ICS=inhaled corticosteroid; LABA=long-acting beta2-adrenergic agonist; LAMA=long-acting muscarinic antagonist.

According to GOLD 2018, use of multiple inhalers is one factor that may lead to poor inhaler technique.2 TRELEGY simplifies the delivery of triple therapy for COPD in a once-daily inhalation.

TRELEGY does not replace a rescue inhaler. Patients should be provided a short-acting beta2-agonist, such as albuterol, to treat acute symptoms and be instructed on how it should be used.

At the conclusion of a 4-week, open-label, placebo study of patients with COPD [N=266], 93% demonstrated correct use and rated the ELLIPTA inhaler easy to use.1 Inhalers did not contain active treatment.

ICS (FF) helps decrease inflammation in the lungs. The precise mechanism through which FF affects COPD symptoms is not known.

LABA (VI) stimulates beta2-receptors in the airway smooth muscle, leading to bronchodilation.

LAMA (UMEC) inhibits M3 receptors in the airways to relax smooth muscle tone, leading to bronchodilation.

ICS=inhaled corticosteroid; LABA=long-acting beta2-adrenergic agonist; LAMA=long-acting muscarinic antagonist.

According to GOLD 2018, use of multiple inhalers is one factor that may lead to poor inhaler technique.2 TRELEGY simplifies the delivery of triple therapy for COPD in a once-daily inhalation.

TRELEGY does not replace a rescue inhaler. Patients should be provided a short-acting beta2-agonist, such as albuterol, to treat acute symptoms and be instructed on how it should be used.

At the conclusion of a 4-week, open-label, placebo study of patients with COPD [N=266], 93% demonstrated correct use and rated the ELLIPTA inhaler easy to use.1 Inhalers did not contain active treatment.

Learn more about how TRELEGY combines an ICS/LABA/LAMA in one inhaler

SEE DOSING INFO

Features of the ELLIPTA Inhaler

Breath actuated

Requires no hand-breath coordination

Preloaded

Each inhaler contains 30 doses

Single-step dose activation

A dose is ready when the cover is opened fully. Counter automatically keeps track of remaining doses

For more information, see the Instructions for Use in the Patient Information for TRELEGY.

Stay up-to-date with new information on

trelegy ellipta